183945-52-0

Basic information

• Product Name: 2-Methyl-4-aMino-1-trifluoroMethoxy-benzene
• Synonyms: 2-Methyl-4-aMino-1-trifluoroMethoxy-benzene;3-Methyl-4-(trifluoroMethoxy)aniline
• CAS NO: 183945-52-0
• Molecular Formula: C₈H₈F₃NO
• Molecular Weight: 191.1504296
• EINECS: -0
• Mol File: 183945-52-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 199.1±35.0 °C(Predicted)
• Appearance: /
• Density: 1.288±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.86±0.10(Predicted)
• CAS DataBase Reference: 2-Methyl-4-aMino-1-trifluoroMethoxy-benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-4-aMino-1-trifluoroMethoxy-benzene(183945-52-0)
• EPA Substance Registry System: 2-Methyl-4-aMino-1-trifluoroMethoxy-benzene(183945-52-0)

Safety Data

• Hazardous Substances Data: 183945-52-0(Hazardous Substances Data)

Usage

General Description

2-Methyl-4-amino-1-trifluoromethoxy-benzene is a chemical compound with a complex aromatic structure. It belongs to a group of organic chemicals known as aromatic amines, which contain a benzene ring and one or more amine groups. The term ‘2-methyl’ signifies the presence of a methyl group (-CH3) attached to the second carbon in the ring, and ‘4-amino’ specifies an amine group (-NH2) attached to the fourth. The term '1-trifluoromethoxy' denotes a trifluoromethoxy group (-OCHF3) on the first carbon. The primary applications and properties of this particular compound will depend on its specific reactivity and interactions with other substances, dictated by its unique chemical structure.

Upstream product

• 7783-56-4 antimony(III) fluoride 
• 183945-50-8 1-(bromodifluoromethoxy)-2-methyl-4-nitro-benzene 
• 99-53-6 2-methyl-4-nitrophenol 
• 183945-51-9 1-trifluoromethoxy-2-methyl-4-nitro-benzene 

Relevant articles and documents

Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl- 3-hydroxy. N-[3'-methyl-4'-(trifluoromethyl)phenyl]propenamide and related compounds

The active metabolite (2) of the novel immunosuppressive agent leflunomide (1) has been shown to inhibit the enzyme dihydroorotate dehydrogenase (DHODH). This enzyme catalyzes the fourth step in de novo pyrimidine biosynthesis. A series of analogues of the active metabolite 2 have been synthesized. Their in vivo biological activity determined in rat and mouse delayed type hypersensitivity has been found to correlate well with their in vitro DHODH potency. The most promising compound (3) has shown activity in rat and mouse collagen (II)-induced arthritis models (ED50 = 2 and 31 mg/kg, respectively) and has shown a shorter half-life in man when compared with leflunomide. Clinical studies in rheumatoid arthritis are in progress.